We are live on ! Find out more
SEEL

Seelos Therapeutics, Inc. Common Stock
SEEL

Delisted

SEEL was delisted on the 15th of October, 2024.

Back to rankings

1 hedge funds and large institutions have $4.58M invested in Seelos Therapeutics, Inc. Common Stock in 2013 Q4 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

26% more capital invested

Capital invested by funds: $3.62M → $4.58M (+$957K)

0% more funds holding

Funds holding: 1 → 1 (0)

86% less call options, than puts

Call options by funds: $74K | Put options by funds: $543K

Holders
1
Holders Change
–
Holders Change %
0%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
–
Calls
$74K
Puts
$543K
Net Calls
-$469K
Net Calls Change
-$126K

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
RCM
Rotella Capital Management
Washington
-$31K
2
Wells Fargo
Wells Fargo
California
-$2K
Name Holding Trade Value Shares
Change 		Change in
Stake
BNP Paribas Financial Markets
26
BNP Paribas Financial Markets
France
$572 – – –
Manulife (Manufacturers Life Insurance)
27
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$2 – – –
RCM
28
Rotella Capital Management
Washington
– -$31K – –
Wells Fargo
29
Wells Fargo
California
– -$2K – –
1
2

SEEL Hedge Fund Activity: Q4 2013 in Review

1 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Seelos Therapeutics, Inc. Common Stock (SEEL) for Q4 2013, worth a combined $4.58M — up 26% from $3.62M a quarter earlier.

Fund positioning in SEEL was balanced in Q4 2013: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.

The largest seller was Rotella Capital Management, cutting an estimated $31K.

  • 1 institutional investor held Seelos Therapeutics, Inc. Common Stock (SEEL) as of Q4 2013, unchanged from Q3 2013.
  • Funds reported $4.58M of Seelos Therapeutics, Inc. Common Stock stock for Q4 2013, up 26% quarter-over-quarter.
  • 0 funds opened new Seelos Therapeutics, Inc. Common Stock positions in Q4 2013 and 0 closed out.
  • The largest Seelos Therapeutics, Inc. Common Stock seller in Q4 2013 was Rotella Capital Management, an estimated $31K sold.

Based on aggregated 13F filings for Q4 2013.